Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (191-200 of 224) with videos related to

Pageof 23
Sort By:
The Journal of Clinical Investigation|June 4, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancerJuliet Carmichael, Ines Figueiredo, Bora Gurel, et al.
Cancer Discovery|October 31, 2018
Cells Lacking the <i>RB1</i> Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for SurvivalMatthew G Oser, Raquel Fonseca, Abhishek A Chakraborty, et al.
Cancer Research|June 22, 2017
Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma SubtypesEmmy D G Fleuren, Myrella Vlenterie, Winette T A van der Graaf, et al.
Cancer Discovery|April 29, 2017
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Joaquin Mateo, Wei Yuan, et al.
Nature|August 13, 2025
NASP modulates histone turnover to drive PARP inhibitor resistanceSarah C Moser, Anna Khalizieva, Josef Roehsner, et al.
Cancer Discovery|April 4, 2018
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast CancerIlirjana Bajrami, Rebecca Marlow, Marieke van de Ven, et al.
Nature|July 20, 2018
The shieldin complex mediates 53BP1-dependent DNA repairSylvie M Noordermeer, Salomé Adam, Dheva Setiaputra, et al.
Scientific Reports|July 15, 2018
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAnessHarriett Holme, Aditi Gulati, Rachel Brough, et al.
Nature Genetics|July 10, 2026
The PRECISE European initiative for cancer-vulnerability mapping and predictionFrancesco Iorio, Mathew J Garnett, Pedro Beltrao, et al.
Cancer Research|June 25, 2017
Functionally Null <i>RAD51D</i> Missense Mutation Associates Strongly with Ovarian CarcinomaBarbara Rivera, Massimo Di Iorio, Jessica Frankum, et al.
Pageof 23

Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
The Journal of Clinical Investigation|June 4, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancerJuliet Carmichael, Ines Figueiredo, Bora Gurel, et al.
Cancer Discovery|October 31, 2018
Cells Lacking the <i>RB1</i> Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for SurvivalMatthew G Oser, Raquel Fonseca, Abhishek A Chakraborty, et al.
Cancer Research|June 22, 2017
Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma SubtypesEmmy D G Fleuren, Myrella Vlenterie, Winette T A van der Graaf, et al.
Cancer Discovery|April 29, 2017
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Joaquin Mateo, Wei Yuan, et al.
Nature|August 13, 2025
NASP modulates histone turnover to drive PARP inhibitor resistanceSarah C Moser, Anna Khalizieva, Josef Roehsner, et al.
Cancer Discovery|April 4, 2018
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast CancerIlirjana Bajrami, Rebecca Marlow, Marieke van de Ven, et al.
Nature|July 20, 2018
The shieldin complex mediates 53BP1-dependent DNA repairSylvie M Noordermeer, Salomé Adam, Dheva Setiaputra, et al.
Scientific Reports|July 15, 2018
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAnessHarriett Holme, Aditi Gulati, Rachel Brough, et al.
Nature Genetics|July 10, 2026
The PRECISE European initiative for cancer-vulnerability mapping and predictionFrancesco Iorio, Mathew J Garnett, Pedro Beltrao, et al.
Cancer Research|June 25, 2017
Functionally Null <i>RAD51D</i> Missense Mutation Associates Strongly with Ovarian CarcinomaBarbara Rivera, Massimo Di Iorio, Jessica Frankum, et al.
Pageof 23